India plans to expand access to new TB drug

The Delhi High Court’s ruling in the recent landmark lawsuit that granted an 18-year old Indian girl with XDR-TB access to bedaquiline has led health advocates to seek inclusion of delamanid in the Indian government’s Revised National Tuberculosis Control Program. “It is time the government enforces public health safeguards in the patent law and licenses the drug to generic firms so that they can manufacture it for government supplies,” said Paul Lhungdim from the Delhi Network of Positive People.

Read more about the results of the lawsuit and how patient advocacy groups are moving forward here.